Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Assets Average (2016 - 2025)

Protalix BioTherapeutics (PLX) has 14 years of Assets Average data on record, last reported at $80.4 million in Q3 2025.

  • For Q3 2025, Assets Average rose 4.99% year-over-year to $80.4 million; the TTM value through Sep 2025 reached $80.4 million, up 4.99%, while the annual FY2024 figure was $78.9 million, 12.57% up from the prior year.
  • Assets Average reached $80.4 million in Q3 2025 per PLX's latest filing, up from $76.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $105.5 million in Q2 2021 and bottomed at $56.2 million in Q4 2022.
  • Average Assets Average over 5 years is $77.9 million, with a median of $77.5 million recorded in 2023.
  • Peak YoY movement for Assets Average: crashed 38.85% in 2022, then surged 52.9% in 2023.
  • A 5-year view of Assets Average shows it stood at $78.6 million in 2021, then decreased by 28.41% to $56.2 million in 2022, then soared by 52.9% to $86.0 million in 2023, then dropped by 21.52% to $67.5 million in 2024, then rose by 19.09% to $80.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $80.4 million in Q3 2025, $76.2 million in Q2 2025, and $73.7 million in Q1 2025.